ClinicalTrials.gg
CompletedNCT00175019EXCELUpdated Jul 27, 2010Results posted

Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010

A Phase 3 interventional study of Febuxostat and Febuxostat in Gout, sponsored by Takeda. Completed. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2010-07-27.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,086
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing febuxostat in Gout — 1 open to participants now, 1 under way, none of them phase 3. Febuxostat · Gout.

Enrollment
3rd of 29
1,086 · median 109
Started
2003
with 1 other
Phase 3
10 of 29
none open now
Registered
4th of 29
by date
Lead sponsor
11 of 29
Takeda

Among the 29 studies testing febuxostat in Gout, this one is the 3rd largest by enrollment, is one of 2 that started in 2003, is one of 10 in phase 3, and was the 4th registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

1 of the 29 studies testing febuxostat in Gout is open now. Recruiting first, the newest first:

About febuxostat

Febuxostat: first FDA approval 2009 (ULORIC), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing febuxostat in Gout, or all of them as a file.
02

Study summary

The purpose of this study is to determine the long-term safety of febuxostat, once daily (QD), compared to allopurinol in reducing serum urate levels in subjects with gout.

Read the detailed description

Uric acid is the end product of purine degradation in humans. Hyperuricemia, a urate concentration in serum exceeding the limit of urate solubility (approximately 7.0 mg/dL), is a common biochemical abnormality. Aberrations in any of the multiple mechanisms involved in the production and/or excretion of uric acid may increase serum urate concentrations, with persistent hyperuricemia as a marker for extracellular fluid monosodium urate supersaturation. As such, hyperuricemia is a necessary (but often insufficient) risk factor for monosodium urate crystal deposition in tissues and is the fundamental pathophysiological process underlying the clinical manifestations of gout, which is a chronic disease characterized by urate crystal formation and deposition in joints and bones. Gout may progress from episodic attacks of acute inflammatory arthritis to a disabling chronic disorder characterized by deforming arthropathy; destructive deposits of urate crystals (tophi) in bones, joints, and other organs; structural and functional renal impairment due to interstitial urate crystal deposition; and urinary tract stones composed entirely or partially of uric acid crystals. Management of gout requires chronic treatment aimed at lowering serum urate levels into a subsaturating range (usually \<6.0 mg/dL) in which crystal formation and deposition are prevented or reversed.

Febuxostat (TMX-67) is a non-purine selective xanthine oxidase inhibitor being developed as an orally administered agent for the management of hyperuricemia in patients with gout.

This study was originally designed and initiated having all subjects initially assigned to 80 mg febuxostat provided as an 80 mg tablet, to be administered orally. Subjects could be titrated to 120 mg, provided as one 40 and 80 mg tablet, between Months 2 and 6, if their serum uric acid rose > 6.0 mg/dL; the dose could be down-titrated to 80 mg if the serum uric acid decreased to \< 3.0 mg/dL.

The protocol was amended to add a comparator arm, and to have subjects randomized to 80 or 120 mg febuxostat or allopurinol (100 or 300 mg, dependent on renal function). The information below reflects the treatments following the implementation of the revised protocol.

03

Conditions studied

  • Gout

Browse trials for

Keywords

  • uric acid
  • xanthine oxidase
  • hyperuricemia
  • tophi
  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is receiving thiazide diuretic therapy (only to subjects randomized to or receiving febuxostat).
  • Has a serum urate level less than 8.0 mg/dL and is not taking uric acid-lowering therapy (other than allopurinol or febuxostat).
  • Has participated in a clinical study in which febuxostat was administered.
  • Is completing Phase 3 Studies C02-009 or C02-010.
  • Must not have experienced any serious study drug-related adverse events in the previous study.
  • Females of who are sexually active must agree to use adequate , and can neither be pregnant nor lactating from Screening throughout the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Has had any other significant medical condition as defined by the investigator that would interfere with the treatment, safety, or compliance with the protocol.
  • Is intolerant of allopurinol.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,086 participants (actual)

Study arms

  • Experimental
    Febuxostat 80 mg QD

    Drug: Febuxostat

  • Experimental
    Febuxostat 120 mg QD

    Drug: Febuxostat

  • Active comparator
    Allopurinol QD

    Drug: Allopurinol

Interventions

  • Febuxostat 80 mg, tablets, orally, once daily.

    Also known as: TMX-67, Tei-6720, Uloric

  • Febuxostat 120 mg, tablets, orally, once daily.

    Also known as: TMX-67, Tei-6720, Uloric

  • Allopurinol 100 mg or 300 mg, tablets, orally, once daily.

    Also known as: Zyloprim

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 1.

    Serum urate values were obtained at the Month 1 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 1 visit was summarized.

    Time frame: Month 1

  2. Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 12.

    Serum urate values were obtained at the Month 12 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 12 visit was summarized.

    Time frame: Month 12

  3. Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 24.

    Serum urate values were obtained at the Month 24 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 24 visit was summarized.

    Time frame: Month 24

  4. Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 36.

    Serum urate values were obtained at the Month 36 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 36 visit was summarized.

    Time frame: Month 36

  5. Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Last Visit on Treatment.

    The percentage of subjects whose serum urate was \<6.0 mg/dL at the last visit on treatment was summarized. The last visit on treatment was the last visit at which a serum urate value was collected prior to any changes in drug and/or dose from the initial treatment assignment.

    Time frame: Last Visit on treatment (up to 40 months).

Secondary outcomes

  1. Percent Change in Serum Urate Levels From Baseline to the Last Visit on Treatment.

    The percent change in serum urate from baseline to the last visit on treatment was summarized. The last visit on treatment was the last visit at which a serum urate value was collected prior to any changes in drug and/or dose from the initial treatment assignment.

    Time frame: Last Visit on treatment (up to 40 months).

  2. Percent Change From Baseline in Primary Tophus Size at Month 12 for Subjects With Palpable Tophi Measured at Baseline.

    The area of the primary tophus was calculated based on the length and width of the tophus measured at the Month 12 visit. The percent change from baseline in primary tophus size to the Month 12 visit was summarized.

    Time frame: Month 12

  3. Percent Change From Baseline in Primary Tophus Size at Month 24 for Subjects With Palpable Tophi Measured at Baseline.

    The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and Month 24 visit. The percent change from baseline in primary tophus size to the Month 24 visit was summarized.

    Time frame: Month 24

  4. Percent Change From Baseline in Primary Tophus Size at Month 36 for Subjects With Palpable Tophi Measured at Baseline.

    The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and Month 36 visit. The percent change from baseline in primary tophus size to the Month 36 visit was summarized.

    Time frame: Month 36

  5. Percent Change From Baseline in Primary Tophus Size at Final Visit for Subjects With Palpable Tophi Measured at Baseline.

    The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and final visit. The percent change from baseline in primary tophus size to the final visit was summarized.

    Time frame: Final Visit (up to 40 months).

  6. Percent Change From Baseline in the Total Number of Tophi for Subjects With Palpable Tophi at Final Visit.

    The number of tophi were counted at baseline and final visits. The percent change from baseline in the number of tophi to the final visit was summarized.

    Time frame: Final Visit (up to 40 months).

  7. Percentage of Subjects Requiring Treatment for Gout Flare up to Month 12.

    The percentage of subjects requiring treatment for gout flare during the first twelve months of final stable treatment was summarized.

    Time frame: Month 12

  8. Percentage of Subjects Requiring Treatment for Gout Flare After Month 12.

    The percentage of subjects requiring treatment for gout flare after the first 12 months of final stable treatment was summarized.

    Time frame: After Month 12 to Final Visit

07

Results

Posted Sep 7, 2009
Limitations and caveats
Subjects may receive \>1 treatment. Adverse events are summarized by treatment at time of observation and subjects who receive \>1 treatment are summarized for each treatment they receive, so subjects at risk will not match number of participants.

Participant flow

Subjects were enrolled at 174 investigative sites, including 168 in the United States and 6 in Canada, from 28 July 2003 to 26 February 2007.

Participant flow — Overall Study
MilestoneFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol QD
Started60638892
Completed41221735
Not completed19417157
Withdrew: Adverse event54222
Withdrew: Protocol violation633
Withdrew: Lost to follow-up42399
Withdrew: Did not continue under amendment 4112
Withdrew: Personal reason(s)39318
Withdrew: Therapeutic failure103822
Withdrew: Gout flare230
Withdrew: Reason not specified403411

Outcome measures

SecondaryPercent Change in Serum Urate Levels From Baseline to the Last Visit on Treatment.

The percent change in serum urate from baseline to the last visit on treatment was summarized. The last visit on treatment was the last visit at which a serum urate value was collected prior to any changes in drug and/or dose from the initial treatment assignment.

Time frame:
Last Visit on treatment (up to 40 months).
Reported as:
Mean · percent change from baseline
Percent Change in Serum Urate Levels From Baseline to the Last Visit on Treatment.
percent change from baselineFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol QD
Percent Change in Serum Urate Levels From Baseline to the Last Visit on Treatment.-46.69 ± 17.43-52.99 ± 19.12-32.17 ± 17.71
SecondaryPercent Change From Baseline in Primary Tophus Size at Month 12 for Subjects With Palpable Tophi Measured at Baseline.

The area of the primary tophus was calculated based on the length and width of the tophus measured at the Month 12 visit. The percent change from baseline in primary tophus size to the Month 12 visit was summarized.

Time frame:
Month 12
Reported as:
Median · percent change from baseline
Percent Change From Baseline in Primary Tophus Size at Month 12 for Subjects With Palpable Tophi Measured at Baseline.
percent change from baselineFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol QD
Percent Change From Baseline in Primary Tophus Size at Month 12 for Subjects With Palpable Tophi Measured at Baseline.-82 (-100 to -40)-79 (-100 to -26)-56 (-100 to -16)
PrimaryPercentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 1.

Serum urate values were obtained at the Month 1 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 1 visit was summarized.

Time frame:
Month 1
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 1.
percentage of subjectsFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol QD
Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 1.80.887.046.0
PrimaryPercentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 12.

Serum urate values were obtained at the Month 12 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 12 visit was summarized.

Time frame:
Month 12
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 12.
percentage of subjectsFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol QD
Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 12.88.986.382.2
PrimaryPercentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 24.

Serum urate values were obtained at the Month 24 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 24 visit was summarized.

Time frame:
Month 24
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 24.
percentage of subjectsFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol QD
Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 24.89.387.278.6
PrimaryPercentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 36.

Serum urate values were obtained at the Month 36 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 36 visit was summarized.

Time frame:
Month 36
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 36.
percentage of subjectsFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol QD
Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 36.90.891.590.0
PrimaryPercentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Last Visit on Treatment.

The percentage of subjects whose serum urate was \<6.0 mg/dL at the last visit on treatment was summarized. The last visit on treatment was the last visit at which a serum urate value was collected prior to any changes in drug and/or dose from the initial treatment assignment.

Time frame:
Last Visit on treatment (up to 40 months).
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Last Visit on Treatment.
percentage of subjectsFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol QD
Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Last Visit on Treatment.70.882.032.6
SecondaryPercent Change From Baseline in Primary Tophus Size at Month 24 for Subjects With Palpable Tophi Measured at Baseline.

The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and Month 24 visit. The percent change from baseline in primary tophus size to the Month 24 visit was summarized.

Time frame:
Month 24
Reported as:
Median · percent change from baseline
Percent Change From Baseline in Primary Tophus Size at Month 24 for Subjects With Palpable Tophi Measured at Baseline.
percent change from baselineFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol QD
Percent Change From Baseline in Primary Tophus Size at Month 24 for Subjects With Palpable Tophi Measured at Baseline.-100 (-100 to -54)-96 (-100 to -52)-87 (-98 to -29)
SecondaryPercent Change From Baseline in Primary Tophus Size at Month 36 for Subjects With Palpable Tophi Measured at Baseline.

The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and Month 36 visit. The percent change from baseline in primary tophus size to the Month 36 visit was summarized.

Time frame:
Month 36
Reported as:
Median · percent change from baseline
Percent Change From Baseline in Primary Tophus Size at Month 36 for Subjects With Palpable Tophi Measured at Baseline.
percent change from baselineFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol QD
Percent Change From Baseline in Primary Tophus Size at Month 36 for Subjects With Palpable Tophi Measured at Baseline.-83 (-83 to -83)——
SecondaryPercent Change From Baseline in Primary Tophus Size at Final Visit for Subjects With Palpable Tophi Measured at Baseline.

The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and final visit. The percent change from baseline in primary tophus size to the final visit was summarized.

Time frame:
Final Visit (up to 40 months).
Reported as:
Median · percent change from baseline
Percent Change From Baseline in Primary Tophus Size at Final Visit for Subjects With Palpable Tophi Measured at Baseline.
percent change from baselineFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol QD
Percent Change From Baseline in Primary Tophus Size at Final Visit for Subjects With Palpable Tophi Measured at Baseline.-96 (-100 to -42)-84 (-100 to -16)-67 (-100 to 0)
SecondaryPercent Change From Baseline in the Total Number of Tophi for Subjects With Palpable Tophi at Final Visit.

The number of tophi were counted at baseline and final visits. The percent change from baseline in the number of tophi to the final visit was summarized.

Time frame:
Final Visit (up to 40 months).
Reported as:
Mean · percent change from baseline
Percent Change From Baseline in the Total Number of Tophi for Subjects With Palpable Tophi at Final Visit.
percent change from baselineFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol QD
Percent Change From Baseline in the Total Number of Tophi for Subjects With Palpable Tophi at Final Visit.-59.9 ± 45.9-58.3 ± 42.5-48.7 ± 42.5
SecondaryPercentage of Subjects Requiring Treatment for Gout Flare up to Month 12.

The percentage of subjects requiring treatment for gout flare during the first twelve months of final stable treatment was summarized.

Time frame:
Month 12
Reported as:
Number · percentage of subjects
Percentage of Subjects Requiring Treatment for Gout Flare up to Month 12.
percentage of subjectsFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol QD
Percentage of Subjects Requiring Treatment for Gout Flare up to Month 12.29.442.528.3
SecondaryPercentage of Subjects Requiring Treatment for Gout Flare After Month 12.

The percentage of subjects requiring treatment for gout flare after the first 12 months of final stable treatment was summarized.

Time frame:
After Month 12 to Final Visit
Reported as:
Number · percentage of subjects
Percentage of Subjects Requiring Treatment for Gout Flare After Month 12.
percentage of subjectsFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol QD
Percentage of Subjects Requiring Treatment for Gout Flare After Month 12.15.319.823.2

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Febuxostat 80 mg QD—98/801 (12.2%)444/801 (55.4%)
Febuxostat 120 mg QD—50/487 (10.3%)257/487 (52.8%)
Allopurinol QD—16/178 (9%)66/178 (37.1%)
Most frequent serious events
Showing 10 of 95
Most frequent serious events
EventFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol QD
Ischaemic Coronary Artery DisordersCardiac disorders17/8013/4872/178
Coronary Artery Disorders not elsewhere classified (NEC)Cardiac disorders13/8016/4871/178
Abdominal and Gastrointestinal InfectionsInfections and infestations3/8012/4872/178
Spine and Neck DeformitiesMusculoskeletal and connective tissue disorders1/8010/4872/178
Cholecystitis and CholelithiasisHepatobiliary disorders7/8011/4871/178
Lower Respiratory Tract and Lung InfectionsInfections and infestations7/8012/4870/178
OsteoarthropathiesMusculoskeletal and connective tissue disorders3/8014/4870/178
Central Nervous System Haemorrhages and CVANervous system disorders6/8012/4870/178
Infections NECInfections and infestations5/8010/4870/178
Pulmonary Thrombotic and Embolic ConditionsRespiratory, thoracic and mediastinal disorders5/8010/4871/178
Most frequent other events
Most frequent other events
EventFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol QD
Upper Respiratory Tract InfectionsInfections and infestations246/801119/48730/178
Musculoskeletal and Connective Tissues Signs and Symptoms NECMusculoskeletal and connective tissue disorders140/80182/48723/178
Joint Related Signs and SymptomsMusculoskeletal and connective tissue disorders100/80150/48712/178
Vascular Hypertensive Disorders NECVascular disorders67/80141/4875/178
Headache NECNervous system disorders45/80138/4877/178
Lower Respiratory Tract and Lung InfectionsInfections and infestations60/80127/4876/178
Diarrhoea (Excl Infective)Gastrointestinal disorders38/80133/4874/178
Oedema NECGeneral disorders49/80117/4873/178
Influenza Viral InfectionsInfections and infestations44/80116/4872/178
Dermatitis and EczemaSkin and subcutaneous tissue disorders44/80123/4872/178

Baseline characteristics

Age Continuous
Age Continuous(years)Febuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol QDTotal
Mean53.0 ± 11.7448.4 ± 11.0251.3 ± 12.7251.2 ± 11.76
Sex: Female, Male
Sex: Female, Male(Participants)Febuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol QDTotal
Female2517244
Male581371901042
Presence of Tophus
Presence of Tophus(participants)Febuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol QDTotal
Present1168315214
Absent49030577872
Race/Ethnicity
Race/Ethnicity(participants)Febuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol QDTotal
Asian159428
Black or African American47331696
White49929964862
Hispanic3029766
Other1518134
Renal Function
Renal Function(participants)Febuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol QDTotal
Normal593381921066
Impaired137020
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m²)Febuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol QDTotal
Mean31.9 ± 5.4934.1 ± 6.7132.4 ± 5.5831.9 ± 5.49
Serum Urate
Serum Urate(mg/dL)Febuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol QDTotal
Mean9.65 ± 1.2010.05 ± 1.299.83 ± 1.279.81 ± 1.25
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009 Jun;36(6):1273-82. doi: 10.3899/jrheum.080814. Epub 2009 Mar 13. PubMed 19286847 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2003, a primary completion of Feb 2007 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2009, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 15, 2005
Start
Jul 2003
Primary completionActual
Feb 2007
CompletionActual
Feb 2007
Results first posted
Sep 7, 2009
Last update
Jul 27, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00175019
Lead sponsor
Takeda
First posted
Sep 15, 2005
Start date
Jul 2003
Primary completion
Feb 2007
Completion
Feb 2007
Results posted
Sep 7, 2009
Last update
Jul 27, 2010

Study contacts

Medical Director
study chair · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Febuxostat

Start the discussion